Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Recruiting · Phase 1, Phase 2 · NCT03681561
Conditions: Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $5,250
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 54
About the trial
- Sponsor
- Veronika Bachanova (with Incyte Corporation, Bristol-Myers Squibb)
- Tested
- Ruxolitinib (drug), Nivolumab (drug)
- Dates
- Started 2018-09-13; completion 2027-07
- Results posted
- Not yet
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $5,250 in research payments for this study in 2025 (1 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.